Modality
Cell Therapy
MOA
Anti-Tau
Target
WEE1
Pathway
STING
LGSNarcolepsyOCD
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
Jun 2020
→ Oct 2029
NDA/BLACurrent
NCT03790925
900 pts·Narcolepsy
2025-04→2029-10·Terminated
NCT05318527
156 pts·Narcolepsy
2020-06→2028-11·Recruiting
1,056 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-10-146mo awayEMA Filing· LGS
2028-11-082.6y awayPh3 Readout· Narcolepsy
2029-10-143.5y awayPh3 Readout· Narcolepsy
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Termina…
Catalysts
EMA Filing
2026-10-14 · 6mo away
LGS
Ph3 Readout
2028-11-08 · 2.6y away
Narcolepsy
Ph3 Readout
2029-10-14 · 3.5y away
Narcolepsy
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03790925 | NDA/BLA | Narcolepsy | Terminated | 900 | SeizFreq |
| NCT05318527 | NDA/BLA | Narcolepsy | Recruiting | 156 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET |